| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_792c873e0b1c08676cf8876febb2a281
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee27036a6ca3794066a07b66b57e5eeb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f983144b8c9c009d80f861194aae3d4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate |
1992-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f63b25da206c5071992394c8d315ca40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3670795b362f95986fd6ab401f62e7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0a4e7a2646c787aa889f377909901f5 |
| publicationDate |
1993-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9306856-A1 |
| titleOfInvention |
Treating ophthalmic fibrosis using interferon-alpha |
| abstract |
The present invention relates to the use of topical interferon-α for the treatment of various forms of fibrosis in and around the eye arising from various ophthalmic diseases and procedures. Specifically the invention relates to alleviation of corneal scarring after laser photoablative refractive keratectomy (PRK). It aslo relates to the alleviation of posterior (lens) capsular opacification after extracapsular cataract surgery with lens implant; the alleviation of wound scarring following glaucoma filtration surgery. Interferon-α may also be used to coat the lens implant prior to or during implantation. It may also possibly be injected into the eye during eye surgery for inhibiting posterior capsule opacification after cataract surgery and in addition may be injected into the vitreous body to prevent retinal fibrosis and proliferative vitreo-retinopathy, and injected subconjunctivally to inhibit fibrosis and scarring following glaucoma filtration surgery. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9829069-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0797998-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9629092-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0797998-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9829069-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006136116-A1 |
| priorityDate |
1991-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |